Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 350 participants.

Also called NCT01798706

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 350 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01798706
  • EudraCT 2012-003292-19
Main results
  • Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial Diabetes care, 2017-04 DOI, PubMed 28188240

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Bulgaria, Canada, Denmark, Germany, Norway, Peru, Poland, South Africa, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01798706. Randomized; quadruple masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Acronym
GetGoal-O
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Placebo
Intervention (Drug)
Antidiabetic background therapy
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01798706
Content hash
0e2229039a86174f928e24f443eb1b1d325b48711673f91e0a31376548465d2f